Sun Pharmaceutical Industries’ subsidiary has been granted a tentative approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Plavix, clopidogrel tablets USP.
These generic clopidogrel tablets USP, 75 mg are therapeutic equivalents of Sanofi Aventis’s Plavix tablets. Clopidogrel tablets USP have annual sale of approximately $6 billion in the US.
Clopidogrel tablets USP are indicated for the treatment of acute coronary syndrome, recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease.
Recently, the company’s had announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Uroxatral ER, alfuzosin hydrochloride extended release tablets
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1903.00 |
| Dr. Reddys Labs. | 1353.75 |
| Cipla | 1452.35 |
| Zydus Lifesciences | 1152.90 |
| Lupin | 2489.85 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: